

DAFTAR PUSTAKA

- Abou-Setta, A. M., Mousavi, S. S., Spooner, C., Schouten, J. R., Pasichnyk, D., Armijo-Olivo, S., Beaith, A., Seida, J. C., Dursun, S., Newton, A. S., & Hartling, L. (2012). *Introduction. In First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness* [Internet]. Agency for Healthcare Research and Quality (US). <https://www.ncbi.nlm.nih.gov/books/NBK107237/>
- Agaba, D. C., Migisha, R., Namayanja, R., Katamba, G., Lugobe, H. M., Aheisibwe, H., Twesigomwe, G., & Ashaba, S. (2019). Prevalence and Associated Factors of Metabolic Syndrome among Patients with Severe Mental Illness Attending a Tertiary Hospital in Southwest Uganda. *BioMed Research International*, 2019, e1096201. <https://doi.org/10.1155/2019/1096201>
- Andari, S. (2017). Pelayanan Sosial Panti Berbasis Agama dalam Merehabilitasi Penderita Skizofrenia. 16(2), 195–208.
- Arania, R., Triwahyuni, T., Esfandiari, F., & Nugraha, F. R. (2021). Hubungan antara Usia, Jenis Kelamin dan Tingkat Pendidikan dengan Kejadian Diabetes Mellitus di Klinik Mardi Waluyo Lampung Tengah. *Jurnal Medika Malahayati*, 5(3), 146–153. <https://doi.org/10.33024/jmm.v5i3.4200>
- Arif, I. S. (2006). *Skizofrenia Memahami Dinamika Keluarga Pasien*. Bandung: Refika Aditama
- Benson, K. L., & Zarcone, V. P. (2005). *Schizophrenia. In M. H. Kryger, T. Roth, & W. C. Dement (Eds.), Principles and Practice of Sleep Medicine (Fourth Edition)* (pp. 1327–1336). W.B. Saunders. <https://doi.org/10.1016/B0-72-160797-7/50120-8>
- Bernardo, M., Rico-Villademoros, F., García-Rizo, C., Rojo, R., & Gómez-Huelgas, R. (2021). Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies. *Advances in Therapy*, 38(5), 2491–2512. <https://doi.org/10.1007/s12325-021-01689-8>
- Bitter, I. & Professor of Psychiatry and Chair, Department of Psychiatry and Psychotherapy, Semmelweis University. (2006). *Pharmacological Treatment of Schizophrenia*. *European Neurological Review*, 1, 93. <https://doi.org/10.17925/ENR.2006.00.01.93>
- Campagna, D., Alamo, A., Di Pino, A., Russo, C., Calogero, A. E., Purrello, F., & Polosa, R. (2019). Smoking and diabetes: Dangerous liaisons and confusing relationships. *Diabetology & Metabolic Syndrome*, 11(1), 85. <https://doi.org/10.1186/s13098-019-0482-2>
- Charlson, F. J., Ferrari, A. J., Santomauro, D. F., Diminic, S., Stockings, E., Scott, J. G., McGrath, J. J., & Whiteford, H. A. (2018). Global Epidemiology and Burden of Schizophrenia: Findings from the Global Burden of Disease Study 2016. *Schizophrenia Bulletin*, 44(6), 1195–1203. <https://doi.org/10.1093/schbul/sby058>
- Chen, Q., Cai, Z., Mao, P., Zhai, Y.-M., Mitchell, P. B., & Tang, Y. (2008). Effects of Risperidon on glucose metabolism in Chinese patients with schizophrenia: A prospective study. *Journal of Psychiatric Research*, 43(2), 124–128. <https://doi.org/10.1016/j.jpsychires.2008.03.004>

- Chia, C. W., Egan, J. M., & Ferrucci, L. (2018). Age-Related Changes in Glucose Metabolism, Hyperglycemia, and Cardiovascular Risk. *Circulation Research*, 123(7), 886–904. <https://doi.org/10.1161/CIRCRESAHA.118.312806>
- Chisholm-Burns, M. A. (Ed.). (2016). *Pharmacotherapy principles & practice* (Fourth edition). McGraw-Hill Education.
- Cohen, D., Stolk, R. P., Grobbee, D. E., & Gispen-de Wied, C. C. (2006). Hyperglycemia and Diabetes in Patients with Schizophrenia or Schizoaffective Disorders. *Diabetes Care*, 29(4), 786–791. <https://doi.org/10.2337/diacare.29.04.06.dc05-1261>
- Correll, C. U., Frederickson, A. M., Kane, J. M., & Manu, P. (2007). Does antipsychotic polypharmacy increase the risk for metabolic syndrome? *Schizophrenia Research*, 89(1–3), 91–100. <https://doi.org/10.1016/j.schres.2006.08.017>
- Dania, H., Faridah, I. N., Rahmah, K. F., Abdulah, R., Barliana, M. I., & Perwitasari, D. A. (2019). Hubungan Pemberian Terapi Antipsikotik terhadap Kejadian Efek Samping Sindrom Ekstrapiramidal pada Pasien Rawat Jalan di Salah Satu Rumah Sakit di Bantul, Yogyakarta. *Indonesian Journal of Clinical Pharmacy*, 8(1). <https://doi.org/10.15416/ijcp.2019.8.1.19>
- Departemen Kesehatan RI. (1998). *Pedoman Penggolongan dan Diagnosis Gangguan Jiwa di Indonesia (PPDGJ)*. Edisi III. Dirjen Pelayanan Medis RI. Jakarta.
- Dibben, C. R. M., Khandaker, G. M., Underwood, B. R., O’Loughlin, C., Keep, C., Mann, L., & Jones, P. B. (2016). First-generation antipsychotics: Not gone but forgotten. *BJPsych Bulletin*, 40(2), 93–96. <https://doi.org/10.1192/pb.bp.115.050708>
- Dinan, T. G. (2004). Stress and the genesis of diabetes mellitus in schizophrenia. *The British Journal of Psychiatry*, 184(S47), s72–s75. <https://doi.org/10.1192/bjp.184.47.s72>
- Dwyer, D., Bradley, R., Kablinger, A., & Freeman, A. (2001). Glucose Metabolism in Relation to Schizophrenia and Antipsychotic Drug Treatment. *Annals of Clinical Psychiatry*, 13(2), 103–113. <https://doi.org/10.3109/10401230109148955>
- Farizah, N. A., Fitriany, E., & Nugrahayu, E. Y. (2020). Hubungan Fungsi Sosial dengan Kualitas Hidup Pasien Skizofrenia Rawat Jalan di Rumah Sakit Jiwa Daerah Atma Husada Mahakam Samarinda. *Motiva: Jurnal Psikologi*, 2(2), 43–50. <https://doi.org/10.31293/mv.v2i2.4436>
- Gogos, A., Sbisà, A. M., Sun, J., Gibbons, A., Udawela, M., & Dean, B. (2015). A Role for Estrogen in Schizophrenia: Clinical and Preclinical Findings. *International Journal of Endocrinology*, 2015, 615356. <https://doi.org/10.1155/2015/615356>
- Hany, M., Rehman, B., Azhar, Y., & Chapman, J. (2022). *Schizophrenia. In StatPearls*. StatPearls Publishing. <http://www.ncbi.nlm.nih.gov/books/NBK539864/>
- Handayani, L., Febriani, F., Rahmadanni, A., & Saufi, A. (2017). Faktor Risiko Kejadian Skizofrenia di Rumah Sakit Jiwa Grhasia Daerah Istimewa Yogyakarta (DIY). *Humanitas*, 13(2), 135. <https://doi.org/10.26555/humanitas.v13i2.6069>

- Haupt, D. W., & Newcomer, J. W. (2001). Hyperglycemia and antipsychotic medications. *The Journal of Clinical Psychiatry*, 62 Suppl 27, 15–26; discussion 40–41.
- Heald, A., Pendlebury, J., Anderson, S., Narayan, V., Guy, M., Gibson, M., Haddad, P., & Livingston, M. (2017). Lifestyle factors and the metabolic syndrome in Schizophrenia: A cross-sectional study. *Annals of General Psychiatry*, 16(1), 12. <https://doi.org/10.1186/s12991-017-0134-6>
- Hermita, B.U. (2006). Faktor Determinan Kejadian Diabetes pada Orang Dewasa di Indonesia (Analisis Data Sekunder SKRT 2004). [Universitas Indonesia]. <https://lib.ui.ac.id>
- Ho, B. L., Lee, W. Y., Chou, Y. C., Chen, Y. C., & Chou, Y. H. (2017). Risk of metabolic syndrome and hyperglycaemia among users of typical and atypical antipsychotics: a retrospective cohort study. *Journal of clinical pharmacy and therapeutics*, 42(4), 464–471.
- Holt, R. I. G. (2019). Association Between Antipsychotic Medication Use and Diabetes. *Current Diabetes Reports*, 19(10), 96. <https://doi.org/10.1007/s11892-019-1220-8>
- Idrus, F., Singara, T., Sunarto, D., Syamsuddin, S., & Lisal, S. T. (2021). Abnormalities in Glucose Blood Level during Antipsychotic Treatment in Schizophrenia Patients. *Open Access Macedonian Journal of Medical Sciences*, 9(T3), 340–344. <https://doi.org/10.3889/oamjms.2021.6294>
- Irawan, D. (2010). Prevalensi dan Faktor Risiko Kejadian Diabetes Melitus Tipe 2 di Daerah Urban Indonesia (Analisis Data Sekunder Riskesdas 2007) [Universitas Indonesia]. <https://lib.ui.ac.id>
- Josiassen, R. C., Joseph, A., Kohegyi, E., Stokes, S., Dadvand, M., Paing, W. W., & Shaughnessy, R. A. (2005). Klozapin augmented with Risperidon in the treatment of schizophrenia: A randomized, double-blind, placebo-controlled trial. *The American Journal of Psychiatry*, 162(1), 130–136. <https://doi.org/10.1176/appi.ajp.162.1.130>
- Kementerian Kesehatan RI. (2018). *Riset Kesehatan Dasar 2018*. Kementerian Kesehatan RI. 225.
- Koller, E. A., Cross, J. T., Doraiswamy, P. M., & Schneider, B. S. (2003). Risperidon-associated diabetes mellitus: A pharmacovigilance study. *Pharmacotherapy*, 23(6), 735–744. <https://doi.org/10.1592/phco.23.6.735.32178>
- Komariah, K., & Rahayu, S. (2020). Hubungan Usia, Jenis Kelamin, dan Indeks Massa Tubuh dengan Kadar Gula Darah Puasa pada Pasien Diabetes Mellitus Tipe 2 di Klinik Pratama Rawat Jalan Proklamasi, Depok, Jawa Barat. *Jurnal Kesehatan Kusuma Husada*, 41–50. <https://doi.org/10.34035/jk.v11i1.412>
- Kumar, P., Mishra, D. K., Mishra, N., Ahuja, S., Raghuvanshi, G., & Niranjana, V. (2019). Acute onset clozapine-induced hyperglycaemia: A case report. *General Psychiatry*, 32(2), e100045. <https://doi.org/10.1136/gpsych-2018-100045>
- Lee, P. G., & Halter, J. B. (2017). The Pathophysiology of Hyperglycemia in Older Adults: Clinical Considerations. *Diabetes Care*, 40(4), 444–452. <https://doi.org/10.2337/dc16-1732>
- Lean, M. E. J., & Pajonk, F.-G. (2003). Patients on Atypical Antipsychotic Drugs. *Diabetes Care*, 26(5), 1597–1605. <https://doi.org/10.2337/diacare.26.5.1597>

- Leucht, S., Kissling, W., & Davis, J. M. (2009). Second-generation antipsychotics for schizophrenia: Can we resolve the conflict? *Psychological Medicine*, 39(10), 1591. <https://doi.org/10.1017/S0033291709005455>
- Li, R., Ma, X., Wang, G., Yang, J., & Wang, C. (2016). Why Sex Differences In Schizophrenia? *Journal of Translational Neuroscience*, 1(1), 37–42.
- Libman, I., Haynes, A., Lyons, S., Pradeep, P., Rwagasor, E., Tung, J. Y., Jefferies, C. A., Oram, R. A., Dabelea, D., & Craig, M. E. (2022). ISPAD Clinical Practice Consensus Guidelines 2022: Definition, epidemiology, and classification of diabetes in children and adolescents. *Pediatric Diabetes*, 23(8), 1160–1174. <https://doi.org/10.1111/pedi.13454>
- Lindenmayer, J. P., Nathan, A. M., & Smith, R. C. (2001). Hyperglycemia associated with the use of atypical antipsychotics. *The Journal of Clinical Psychiatry*, 62 Suppl 23, 30–38.
- Mallett, R., Leff, J., Bhugra, D., Pang, D., & Zhao, J. H. (2002). Social environment, ethnicity and schizophrenia. A case-control study. *Social Psychiatry and Psychiatric Epidemiology*, 37(7), 329–335. <https://doi.org/10.1007/s00127-002-0557-4>
- McNeil, S. E., Gibbons, J. R., & Cogburn, M. (2022). *Risperidon In StatPearls*. StatPearls Publishing. <http://www.ncbi.nlm.nih.gov/books/NBK459313/>
- Mordarska, K., & Godziejewska-Zawada, M. (2017). Diabetes in the elderly. *Przegląd Menopauzalny = Menopause Review*, 16(2), 38. <https://doi.org/10.5114/pm.2017.68589>
- Mouri, Mi., & Badireddy, M. (2022). Hyperglycemia. In StatPearls. *StatPearls Publishing*. <http://www.ncbi.nlm.nih.gov/books/NBK430900/>
- Murashita, M., Inoue, T., Kusumi, I., Nakagawa, S., Itoh, K., Tanaka, T., Izumi, T., Hosoda, H., Kangawa, K., & Koyama, T. (2007). Glucose and lipid metabolism of long-term Risperidon monotherapy in patients with schizophrenia. *Psychiatry and Clinical Neurosciences*, 61(1), 54–58. <https://doi.org/10.1111/j.1440-1819.2007.01610.x>
- Nielsen, J., Skadhede, S., & Correll, C. U. (2010). Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia Patients. *Neuropsychopharmacology*, 35(9), 1997–2004. <https://doi.org/10.1038/npp.2010.78>
- Nurrahmani. (2012). *Stop! Diabetes*. Yogyakarta: Araska.
- Nyenwe, E. A., Odia, O. J., Ihekweba, A. E., Ojule, A., & Babatunde, S. (2003). Type 2 diabetes in adult Nigerians: A study of its prevalence and risk factors in Port Harcourt, Nigeria. *Diabetes Research and Clinical Practice*, 62(3), 177–185. <https://doi.org/10.1016/j.diabres.2003.07.002>
- Olfson, M., Gerhard, T., Huang, C., Crystal, S., & Stroup, T. S. (2015). Premature Mortality Among Adults with Schizophrenia in the United States. *JAMA Psychiatry*, 72(12), 1172–1181. <https://doi.org/10.1001/jamapsychiatry.2015.1737>
- Owen, M. J., Sawa, A., & Mortensen, P. B. (2016). Schizophrenia. *Lancet (London, England)*, 388(10039), 86–97. [https://doi.org/10.1016/S0140-6736\(15\)01121-6](https://doi.org/10.1016/S0140-6736(15)01121-6)
- Palmer, B. A., Pankratz, V. S., & Bostwick, J. M. (2005). The lifetime risk of suicide in schizophrenia: A reexamination. *Archives of General Psychiatry*, 62(3), 247–253. <https://doi.org/10.1001/archpsyc.62.3.247>

- Patel, K. R., Cherian, J., Gohil, K., & Atkinson, D. (2014). Schizophrenia: Overview and Treatment Options. *Pharmacy and Therapeutics*, 39(9), 638–645.
- Pahlawati, A., & Nugroho, P. S. (2019). Hubungan Tingkat Pendidikan dan Usia dengan Kejadian Diabetes Melitus di Wilayah Kerja Puskesmas Palaran Kota Samarinda Tahun 2019. *Borneo Student Research (BSR)*, 1(1), 1–5.
- Pramono, D. (2010). Determinan terhadap Timbulnya Skizofrenia pada Pasien Rawat Jalan di Rumah Sakit Jiwa Prof. HB Saanin Padang Sumatera Barat. *Berita Kedokteran Masyarakat*, 26(2), 71 – 80.
- Putra, F., & Mahmudiono, T. (2012). Hubungan Tingkat Konsumsi Karbohidrat, Lemak, dan Dietary Fiber Dengan Kadar Gula Darah Pada Penderita Diabetes Mellitus Tipe 2. *Media Gizi Indonesia*, 2, 1528–1538.
- Riawan, H., Kristanto, C. S., & Ikawati, Z. (2022). Perbandingan Regimen Terapi Antipsikotik Berbasis Risperidon Terhadap Sindrom Ekstrapiramidal, Fungsi Kognitif, dan Gangguan Metabolik Pada Pasien Schizophrenia. *Majalah Farmaseutik*, 18(2). <https://doi.org/10.22146/farmaseutik.v1i1.60346>
- Riduwan dan Akdon. (2010). *Rumus dan Data dalam Analisis Data Statistika*. Bandung: Alfabeta.
- Rissa, M. M., Darmawan, E., & Siwinarni, A. (2020). Profil Penggunaan Obat Kombinasi Risperidon-Klozapin dan Risperidon dengan Antipsikotik Lain pada Pasien Gangguan Mental Psikotik di Rumah Sakit Jiwa Grhasia Yogyakarta: Profile of the Use of Risperidon-Klozapin and Risperidon Combination with Other Antipsychotics in Psychotic Mental Disorders Patients in Grhasia Mental Hospital Yogyakarta. *Jurnal Surya Medika (JSM)*, 5(2), Article 2. <https://doi.org/10.33084/jsm.v5i2.1320>
- Rusdianah, E. (2021). Faktor Keturunan dengan Kejadian Skizofrenia. *Jurnal Keperawatan Jiwa (JKJ): Persatuan Perawat Nasional Indonesia*, 9(3) 685–692.
- Saha, S., Chant, D., & McGrath, J. (2007). A systematic review of mortality in schizophrenia: Is the differential mortality gap worsening over time? *Archives of General Psychiatry*, 64(10), 1123–1131. <https://doi.org/10.1001/archpsyc.64.10.1123>
- Schwinghammer T.L., & DiPiro J.T., & Ellingrod V.L., & DiPiro C.V.(Eds.), (2021). *Pharmacotherapy Handbook*, (Eleventh edition). McGraw Hill. <https://accesspharmacy.mhmedical.com/content.aspx?bookid=3012§ionid=253433827>
- Sefrina, F. (2016). Hubungan Dukungan Keluarga dan Keberfungsian Sosial pada Pasien Skizofrenia Rawat Jalan. *Jurnal Ilmiah Psikologi Terapan*, 4(2), Article 2. <https://doi.org/10.22219/jipt.v4i2.3609>
- Stepnicki, P., Kondej, M., & Kaczor, A. A. (2018). Current Concepts and Treatments of Schizophrenia. *Molecules: A Journal of Synthetic Chemistry and Natural Product Chemistry*, 23(8), 2087. <https://doi.org/10.3390/molecules23082087>.
- Stilo, S. A., & Murray, R. M. (2019). Non-Genetic Factors in Schizophrenia. *Current Psychiatry Reports*, 21(10), 100. <https://doi.org/10.1007/s11920-019-1091-3>

- Suastika, K., Dwipayana, P., Semadi, M. S., & Kuswardhani, R. A. T. (2012). Age is an Important Risk Factor for Type 2 Diabetes Mellitus and Cardiovascular Diseases. *Intech Open*. <http://dx.doi.org/10.5772/52397>
- Susanti, S., & Bistara, D. N. (2018). Hubungan Pola Makan Dengan Kadar Gula Darah Pada Penderita Diabetes Mellitus. *Jurnal Kesehatan Vokasional*, 3(1), Article 1. <https://doi.org/10.22146/jkesvo.34080>
- van Winkel, R., De Hert, M., Wampers, M., Van Eyck, D., Hanssens, L., Scheen, A., & Peuskens, J. (2008). Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. *The Journal of Clinical Psychiatry*, 69(3), 472–479. <https://doi.org/10.4088/jcp.v69n0320>
- Usman, J., Rahman, D., & Sulaiman, N. (2020). Faktor yang Berhubungan dengan Kejadian Diabetes Mellitus pada Pasien di RSUD Haji Makassar. *Jurnal Komunitas Kesehatan Masyarakat*, 2(1), 16–22.
- Wahyudi, A., & Fibriana, A. I. (2016). Faktor Resiko Terjadinya Skizofrenia (Studi Kasus di Wilayah Kerja Puskesmas Pati II). *Public Health Perspective Journal*, 1(1), Article 1. <https://journal.unnes.ac.id/nju/index.php/phpj/article/view/7750>
- Wang, C., Zhang, X., Wang, Z., Han, C., Sun, J., & Ma, J. (2016). Prevalence of metabolic syndrome among patients receiving clozapine and risperidone in Chinese population: a meta-analysis. *International Journal of Clinical and Experimental Medicine*, 9(5), 8708-8717.
- Wells, B. G., DiPiro, J. T., Schwinghammer, T. L., & DiPiro, C. V. (Eds.). (2009). *Pharmacotherapy handbook* (Seventh edition). McGraw-Hill.
- Wells, B. G., DiPiro, J. T., Schwinghammer, T. L., & DiPiro, C. V. (Eds.). (2015). *Pharmacotherapy handbook* (Ninth edition). McGraw-Hill.
- Wijayanti, A., & Puspitosari, W. A. (2014). Hubungan Onset Usia dengan Kualitas Hidup Penderita Skizofrenia di Wilayah Kerja Puskesmas Kasihan II Bantul Yogyakarta. *Mutiara Medika: Jurnal Kedokteran dan Kesehatan*, 14(1), Article 1. <https://doi.org/10.18196/mmjkk.v14i1.2469>
- Zahnia, S., & Sumekar, D. W. (n.d.). *Kajian Epidemiologis Skizofrenia*.